Introduction
Increasing resistance to antimicrobial agents among respiratory tract pathogens is a cause of concern. -Lactamresistant strains of the three most common pathogens, Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis, are being isolated with increasing frequency in many countries, as well as macrolide-and fluoroquinolone-resistant strains of S. pneumoniae. [1] [2] [3] [4] Therefore, there is a need for new antimicrobials with activity against these microorganisms, since the efficacy of the antimicrobials commonly used in the therapy of respiratory tract infections is being compromised. New fluoroquinolones have been developed in an attempt to help improve this situation. Gemifloxacin (SB-265805) is a potent new fluoroquinolone, which has an oxime-derived (amino-methyl) pyrrolidine substituent at C7 conferring activity against Gram-positive and -negative microorganisms. [5] [6] [7] The favourable pharmacokinetics of gemifloxacin make it a promising agent for the therapy of respiratory tract infections. 8 The objective of this study was to determine the in vitro activity of gemifloxacin against recent clinical isolates of S. pneumoniae, H. influenzae and M. catarrhalis, and to compare it with that of other fluoroquinolones.
Materials and methods

Bacterial strains
We tested a total of 302 S. pneumoniae. The clinical isolates were non-duplicate, consecutive and recently obtained in our laboratory from lower respiratory tract infections and blood cultures during the period 1998-1999. Among these, 98 were penicillin-susceptible, 124 were penicillin intermediate (MIC 0.12-1 mg/L) and 80 were penicillin resistant (MIC у 2 mg/L). Twenty-eight per cent (86) of the isolates were also erythromycin resistant (MIC у 1 mg/L), and a total of 44 isolates (14%) were resistant or had intermediate susceptibility to ciprofloxacin (MIC 2-4 mg/L). We also tested a total of 300 non-duplicate, consecutive, recently obtained clinical isolates of H. influenzae [234 -lactamase-negative and 66 (22%) -lactamase-positive] and 28 M. catarrhalis (75% -lactamase-positive) from lower respiratory tract infections and blood cultures during 1998-1999.
National Committee for Clinical Laboratory Standards (NCCLS). 9 The NCCLS breakpoint for ciprofloxacin against H. influenzae (р1 mg/L) was also used for S. pneumoniae and M. catarrhalis. 9 We used commercially prepared dried microdilution panels (SB-265805 surveillance MIC1 and MIC2, Baxter, MicroScan RUO/IUO, Sacramento, CA, USA) manufactured for this study. The panels included gemifloxacin at two-fold increases in concentration from 0.001 to 256 mg/L, trovafloxacin, grepafloxacin, levofloxacin and ciprofloxacin at two-fold increases in concentration from 0.015 to 16 mg/L, and ofloxacin at two-fold increases in concentration from 0.06 to 64 mg/L. Panels were inoculated with isolates suspended in cation-adjusted Mueller-Hinton broth with 3% lysed horse blood for S. pneumoniae and M. catarrhalis, and Haemophilus Test Medium for H. influenzae, to achieve a final inoculum of 4-7 ϫ 10 5 cfu/mL. Escherichia coli ATCC 25922, Staphylococcus aureus ATCC 29213, Enterococcus faecalis ATCC 29212, H. influenzae ATCC 49247 and S. pneumoniae ATCC 49619 were used as control strains in each run. MIC readings were taken after incubation at 35°C for 20-24 h in air.
Results and discussion
Gemifloxacin demonstrated the most potent antimicrobial activity among the quinolones tested against S. pneumoniae, H. influenzae and M. catarrhalis. The comparative in vitro antimicrobial activity of gemifloxacin and other fluoroquinolones is shown in the Table. All 630 isolates were inhibited by gemifloxacin at 0.12 mg/L. MIC 90 s of gemifloxacin, trovafloxacin, grepafloxacin, levofloxacin and ofloxacin against all isolates tested were 0.03, 0.12, 0.12, 1 and 2 mg/L, respectively.
Gemifloxacin had similar high activity against penicillinsusceptible and -resistant S. pneumoniae, erythromycinresistant S. pneumoniae, and -lactamase-positive and -negative H. influenzae and M. catarrhalis. Against S. pneumoniae, gemifloxacin was two-fold more active than grepafloxacin and trovafloxacin, and 16-fold more active than levofloxacin. These results are similar to those found in other studies. 6, 10 Against H. influenzae, the activity of gemifloxacin was two-fold higher than that of grepafloxacin and trovafloxacin, and four-fold higher than that of levofloxacin. Against M. catarrhalis, the activity of gemifloxacin was similar to that of trovafloxacin, and four-fold higher than that of grepafloxacin and levofloxacin (Table) . Gemifloxacin was equally active against -lactamase-positive and -negative M. catarrhalis (MIC 90 0.015 mg/L in both cases, data not shown in the Table) . In the case of S. pneumoniae with reduced susceptibility to ciprofloxacin (MIC у 2 mg/L), gemifloxacin showed excellent activity, although the MIC 90 of gemifloxacin against those isolates was twofold higher (0.06 mg/L) than that found against isolates susceptible to ciprofloxacin (0.03 mg/L). Gemifloxacin is a new fluoroquinolone with improved activity against Gram-positive microorganisms. Several studies have determined the activity of this compound against the most common respiratory tract pathogens. 6, 7, 10 Our results are similar to those found in other studies and show that gemifloxacin is highly active against S. pneumoniae, H. influenzae and M. catarrhalis. The in vitro activity of gemifloxacin against S. pneumoniae appeared to be independent of penicillin and erythromycin susceptibility, and in all cases MICs of gemifloxacin were <0.25 mg/L. Against H. influenzae, gemifloxacin was four-fold more active against -lactamase-negative isolates; however, the MIC 90 of gemifloxacin against -lactamase-positive isolates was 0.03 mg/L. Other studies have shown no differences in the activity of gemifloxacin against -lactamase-positive or -negative strains. 7 The results found in our study may be explained by the fact that the MICs of ciprofloxacin against the population of -lactamase-positive strains studied were higher than those against the -lactamase-negative strains. In the case of M. catarrhalis, the activity of gemifloxacin was independent of -lactamase production. Other reports have demonstrated MICs slightly lower than ours. 7 Gemifloxacin retained good activity against S. pneumoniae with diminished susceptibility to ciprofloxacin.
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The use of newer fluoroquinolones against respiratory tract pathogens diversifies the number of treatments and potentially contributes to decreasing the spread of resistance to other antimicrobial agents by reducing the selective pressure on other antibiotic groups. Gemifloxacin (SB-265805) is a potent new fluoroquinolone with excellent activity against respiratory tract pathogens, including strains with resistance to current antimicrobial therapies.
